In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shire Pharmaceuticals Group PLC

http://www.shire.com

Latest From Shire Pharmaceuticals Group PLC

FDA Approves ReCor’s Renal Denervation System

The US FDA approved ReCor’s Paradise ultrasound renal denervation system, making it the first RDN system to reach the US market. Medtronic hopes its Symplicity Spyral radiofrequency RDN system will be the second RDN system on the US market, but it may face a more difficult path through the approval process.

Approvals Cardiology

Finance Watch: ReCode’s Series B Mega-Round Grows Again With $50m Boost

Private Company Edition: ReCode’s series B venture capital round grew for a third time, now totaling $260m for precision genetic medicines. Also, DalCor closed an $80m series D, manufacturer Nephron amassed $350m, Hyku launched with a $56m seed financing and Magnet emerged with $50m.

Financing Innovation

Cardio Catch-Up: Advisory Panel Gives Recor Momentum Toward US Launch Of RDN System

The majority of FDA’s circulatory systems devices panel agreed that ReCor’s Paradise ultrasound renal denervation system offers a safe and effective therapy for patients with hypertension. The panel’s endorsement means ReCor will likely be the first company to reach the US market with an RDN system.

Advisory Committees Clinical Trials

Cardio Catch-Up: Medtronic Still Has Work To Do On RDN After FDA Advisory Panel

FDA’s circulatory system advisory panel narrowly voted against Medtronic’s Symplicity Spyral, because one of the pivotal trials of the radiofrequency renal denervation system missed its primary endpoint and the patient population evaluated in the trial does not match the requested indication.

Advisory Committees Approvals
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Advanced BioHealing, Inc. (renamed Shire Regenerative Medicine)
    • AesRX LLC
    • Baxalta Incorporated
    • BIKAM Pharmaceuticals Inc.
    • Chatham Therapeutics
    • Dyax Corp.
    • FerroKin BioSciences, Inc.
    • Fibrotech Therapeutics
    • Foresight Biotherapeutics Inc.
    • Gambro AB
    • Immuno-US
    • Jerini AG
    • Lotus Tissue Repair
    • Lumena Pharmaceuticals
    • Meritage Pharma, Inc.
    • Movetis NV
    • New Pervasis Therapeutics, Inc.
    • NPS Pharmaceuticals, Inc.
    • Premacure AB
    • Prism Pharmaceuticals, Inc.
    • River Pharmaceuticals
    • Roberts Pharmaceutical Corporation
    • SARcode Corporation
    • SuppreMol GmbH
    • Synovis Life Technologies, Inc.
    • Transkaryotic Therapies, Inc.
    • ViroPharma Inc.
UsernamePublicRestriction

Register